lly-img

Eli Lilly and Company, Common Stock

LLY

NYQ

$782.12

+$28.44

(3.77%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$743.14B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
134.85
Volume info-icon
This is the total number of shares traded during the most recent trading day.
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
3.83M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.69%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$306.75 L
$794.47 H
$782.12

About Eli Lilly and Company, Common Stock

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/2...more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameLLYSectorS&P500
1-Week Return1.68%-2.06%0.03%
1-Month Return18.69%1.84%3.84%
3-Month Return34.22%10.35%11.14%
6-Month Return40.96%9.35%13.49%
1-Year Return151.15%15.97%30.78%
3-Year Return292.83%33%36.58%
5-Year Return555.79%69.86%97.17%
10-Year Return1533.8%188.37%231.4%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue22.32B24.54B28.32B28.54B34.12B[{"date":"2019-12-31","value":65.41,"profit":true},{"date":"2020-12-31","value":71.91,"profit":true},{"date":"2021-12-31","value":82.99,"profit":true},{"date":"2022-12-31","value":83.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue4.72B5.48B7.31B6.63B6.58B[{"date":"2019-12-31","value":64.56,"profit":true},{"date":"2020-12-31","value":74.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.66,"profit":true},{"date":"2023-12-31","value":89.92,"profit":true}]
Gross Profit17.60B19.06B21.01B21.91B27.55B[{"date":"2019-12-31","value":63.88,"profit":true},{"date":"2020-12-31","value":69.18,"profit":true},{"date":"2021-12-31","value":76.25,"profit":true},{"date":"2022-12-31","value":79.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin78.85%77.66%74.18%76.77%80.73%[{"date":"2019-12-31","value":97.67,"profit":true},{"date":"2020-12-31","value":96.19,"profit":true},{"date":"2021-12-31","value":91.88,"profit":true},{"date":"2022-12-31","value":95.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses11.81B12.21B13.46B13.63B17.22B[{"date":"2019-12-31","value":68.57,"profit":true},{"date":"2020-12-31","value":70.88,"profit":true},{"date":"2021-12-31","value":78.14,"profit":true},{"date":"2022-12-31","value":79.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income4.97B6.06B6.36B7.13B10.33B[{"date":"2019-12-31","value":48.18,"profit":true},{"date":"2020-12-31","value":58.67,"profit":true},{"date":"2021-12-31","value":61.57,"profit":true},{"date":"2022-12-31","value":69.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(28.60M)845.30M(516.00M)(589.70M)(4.08B)[{"date":"2019-12-31","value":-3.38,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-61.04,"profit":false},{"date":"2022-12-31","value":-69.76,"profit":false},{"date":"2023-12-31","value":-483.04,"profit":false}]
Pre-Tax Income5.27B7.23B6.16B6.81B6.55B[{"date":"2019-12-31","value":72.84,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":85.14,"profit":true},{"date":"2022-12-31","value":94.14,"profit":true},{"date":"2023-12-31","value":90.66,"profit":true}]
Income Taxes628.00M1.04B573.80M561.60M1.31B[{"date":"2019-12-31","value":47.79,"profit":true},{"date":"2020-12-31","value":78.85,"profit":true},{"date":"2021-12-31","value":43.66,"profit":true},{"date":"2022-12-31","value":42.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes4.64B6.19B5.58B6.24B5.24B[{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}]
Income From Continuous Operations4.64B6.19B5.58B6.24B5.24B[{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}]
Income From Discontinued Operations3.68B----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income4.64B6.19B5.58B6.24B5.24B[{"date":"2019-12-31","value":74.27,"profit":true},{"date":"2020-12-31","value":99.18,"profit":true},{"date":"2021-12-31","value":89.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.92,"profit":true}]
EPS (Diluted)6.047.938.178.096.32[{"date":"2019-12-31","value":73.93,"profit":true},{"date":"2020-12-31","value":97.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":77.36,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LLY
Cash Ratio 0.11
Current Ratio 0.94
Quick Ratio 0.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LLY
ROA (LTM) 11.88%
ROE (LTM) 48.44%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LLY
Debt Ratio Lower is generally better. Negative is bad. 0.83
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 5.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LLY
Trailing PE 129.94
Forward PE 59.88
P/S (TTM) 20.99
P/B 66.48
Price/FCF NM
EV/R 21.64
EV/Ebitda 86.19
PEG NM

News

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

WHY: NEW YORK, NY - ( NewMediaWire ) - March 03, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. WHAT IS THIS ABOUT: On February 13, 2024, market analyst Kerrisdale Capital released a report entitled “Altimmune Inc. (ALT): Fat Chance” (the “Report”).

3 Mar, 2024 a 10:30 pm The North America Newswire

Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly

This is a close contest, and it''ll go on for at least a few more rounds.

3 Mar, 2024 a 5:51 pm The Motley Fool

Better Buy: Eli Lilly vs. Viking Therapeutics

These two biotechs could eventually go head to head in a fast-growing market.

3 Mar, 2024 a 2:35 pm The Motley Fool

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT

WHY: NEW YORK, NY - ( NewMediaWire ) - March 01, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT) resulting from allegations that Altimmune may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Altimmune securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. WHAT IS THIS ABOUT: On February 13, 2024, market analyst Kerrisdale Capital released a report entitled “Altimmune Inc. (ALT): Fat Chance” (the “Report”).

2 Mar, 2024 a 1:00 am The North America Newswire

Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion

Lilly''s new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

1 Mar, 2024 a 4:35 pm Investor''s Business Daily

FAQs

What is Eli Lilly and Company share price today?

Eli Lilly and Company (LLY) share price today is $782.12

Can Indians buy Eli Lilly and Company shares?

Yes, Indians can buy shares of Eli Lilly and Company (LLY) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LLY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Eli Lilly and Company be purchased?

Yes, you can purchase fractional shares of Eli Lilly and Company (LLY) via the Vested app. You can start investing in Eli Lilly and Company (LLY) with a minimum investment of $1.

How to invest in Eli Lilly and Company shares from India?

You can invest in shares of Eli Lilly and Company (LLY) via Vested in three simple steps:

  • Click on Sign Up or Invest in LLY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Eli Lilly and Company shares
What is Eli Lilly and Company 52-week high and low stock price?

The 52-week high price of Eli Lilly and Company (LLY) is 794.47. The 52-week low price of Eli Lilly and Company (LLY) is 306.75.

What is Eli Lilly and Company price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Eli Lilly and Company (LLY) is 134.85

What is Eli Lilly and Company price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Eli Lilly and Company (LLY) is 66.48

What is Eli Lilly and Company dividend yield?

The dividend yield of Eli Lilly and Company (LLY) is 0.69%

What is the Market Cap of Eli Lilly and Company?

The market capitalization of Eli Lilly and Company (LLY) is $743.14B

What is Eli Lilly and Company’s stock symbol?

The stock symbol (or ticker) of Eli Lilly and Company is LLY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top